an indication that the opinion of a nutrition expert or veterinarian should be sought before using the feed or before extending its period of use.

‘best before ’. followed by the date indicating a certain month in the case of other feed.

the use of fishmeal for young farmed animals of the ruminant species will only be authorised for the production of milk replacers, distributed in dry form and administered after dilution in a given quantity of liquid, intended for the feeding of unweaned ruminants as a supplement to, or substitute for, post-colostral milk before weaning is complete;

In addition, to ensure that the use of fishmeal is only allowed for young animals of ruminant species, such use should be limited to the production of milk replacers, distributed in dry form and administered after dilution in a given quantity of liquid, intended for feeding to young animals of ruminant species as a supplement to, or substitute for, post-colostral milk before weaning is complete.

3. Notifications concerning products including their use as feed submitted under Article 13 of Directive 2001/18/EC before the date of application of this Regulation shall be transformed into applications under Chapter III, Section 1 of this Regulation where the assessment report provided for in Article 14 of Directive 2001/18/EC has not yet been sent to the Commission.

Q-91 Mr. Cummins (Delta South Richmond) With reference to the antimalarial drug mefloquine administered to Canadian Forces bound for Somalia in 1992-93 and the legal framework under which it was available for use and administered: (a) was mefloquine a licensed drug when it was administered to Canadian Forces, if not what was its status, and how was it legally available; (b) were the Canadian Forces participating in the Lariam (mefloquine) Safety Monitoring Study during this period; (c) was the mefloquine administered in accordance with the Lariam Safety Monitoring Study and the Food and Drugs Act; (d) who was the " principal investigator" responsible for the Lariam Safety Monitoring Study in the Canadian Forces; (e) who was the Canadia ...[+++]n Forces physician responsible to the " principal investigator" of the Lariam Safety Monitoring Study; (f) what was the role of Canadian Forces physician, Dr. Martin Tepper, in the Lariam Safety Monitoring Study; (g) who was responsible for the Lariam Safety Monitoring Study at the Department of Health's Health Protection Branch during this period; (h) what was the role and responsibility of the Health Protection Branch under the Lariam Safety Monitoring Study and the Food and Drugs Act and its regulations in regard to the use of mefloquine by Canadian Forces personnel; (i) when did the Health Protection Branch become aware that mefloquine was being administered to Canadian Forces personnel bound for Somalia; (j) what responsibility did the Canadian Forces have under the Lariam Safety Monitoring Study and the Food and Drugs Act prior to the licensing of mefloquine to inform the manufacturer of its use; (k) what responsibility did the Canadian Forces have under the Lariam Safety Monitoring Study and the Food and Drugs Act to the soldiers who were administered the drug; (l) did the Canadian Forces fulfil their responsibility to the manufacturer under the Lariam Safety Monitoring Study and the Food and Dru ...